Johnson & Johnson gets fresh analyst backing, shares trade higher on NYSE

By Anna Wagner, Analysts & Consensus desk. Reviewed prior to publication on 2026-06-23, 18:34.

Johnson & Johnson (US4781601046) remains firmly in Wall Street’s good graces. The New York Stock Exchange-listed healthcare group now counts Leerink Partners among its bulls after an upgrade to Outperform with a stated price target of 265 US dollars, according to trading and sentiment data for JNJ shares. TrendSpider JNJ overview with analyst note

What the analyst upgrade shows

The recent Leerink Partners call shifts Johnson & Johnson from Market Perform to Outperform, signaling a clearer conviction that the stock can outpace the broader US healthcare sector. TrendSpider JNJ overview with analyst note The 265 dollar price target sits notably above the latest JNJ quote in the low-230s to mid-230s, implying upside in the mid-teens percentage range versus current trading levels.

Recent commentary highlights Johnson & Johnson’s 2026 record revenue, an 11 percent year-to-date gain and a 64-year dividend streak as reasons for sustained investor interest. TrendSpider JNJ performance and dividend track record Those data points help underpin the constructive stance from research houses and frame the shares as a core holding within US large-cap healthcare, which includes peers like Pfizer and Merck.

Consensus view and upcoming earnings

Beyond the Leerink call, consensus indicators point to a broadly positive sentiment backdrop for Johnson & Johnson. One sentiment tracker shows JNJ closing at around 231.12 US dollars on 22 June, up roughly 1.2 percent on the day, with extended trading nudging the quote closer to 233.85 US dollars before the next regular session. MarketBeat JNJ trends and sentiment

Trading platforms report that JNJ shares recently changed hands near 235.61 US dollars, with intraday ranges between about 233.37 and 237.85 US dollars and a market capitalization in the region of 567 billion US dollars. Robinhood JNJ quote and market cap The next earnings date is flagged for mid-July 2026, a key moment when management will update investors on the Innovative Medicine and MedTech divisions as well as the group’s pipeline and capital allocation plans. TrendSpider JNJ earnings calendar

The product behind the stock

Johnson & Johnson’s equity story rests on a diversified healthcare portfolio anchored in Innovative Medicine therapies and MedTech devices. One visible consumer-facing line is its Acuvue contact lenses, which sit within the group’s expanded vision care operations in Florida and serve millions of patients requiring corrective eye solutions. Marketscreener summary of J&J Florida vision investment

Where the stock trades today

Johnson & Johnson shares (US4781601046) trade on the New York Stock Exchange at around 235.61 US dollars as of 2026-06-23, 16:00 Eastern Time, based on recent intraday data from major trading platforms. Robinhood JNJ real-time quote

This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities or any other form of financial guidance. Data and prices are based on sources believed to be reliable at the time of publication but may change without notice.